Search Results

physIQ today announced a strategic collaboration with InCarda Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular diseases.

InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-in-class inhaled therapies for cardiovascular diseases, today announced that it has successfully completed an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) for InRhythm™ (flecainide for inhalation) for the treatment of atrial fibrillation.

InCarda Therapeutics, Inc. (“InCarda”), today provided a broad corporate update highlighting significant progress for the company’s last-stage development program for InRhythm™ (flecainide for inhalation) in patients with atrial fibrillation, as well as the expansion of its senior management team.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular diseases, today announced dosing of the first U.S. patient in the company’s multinational INSTANT Phase 2 clinical trial of InRhythm™ (flecainide for inhalation) in patients with recent-onset paroxysmal atrial fibrillation (PAF).

The latest Repare Therapeutics layoffs will include its chief medical officer and could leave the biotech with fewer than 35 employees as it works to advance two Phase I clinical programs.